Does Rapid Drug Desensitization to chemotherapy affect survival outcomes?

MP Berges-Gimeno, LV Carpio-Escalona, F Longo-Muñoz, L Bernal-Rubio, P Lopez-Gonzalez, P Gehlhaar, V Pachon, R Ferreiro-Monteagudo, R Madrigal-Burgaleta, E Alvarez-Cuesta
2019 Journal of investigational allergology & clinical immunology  
Hypersensitivity reactions to oxaliplatin may affect prognosis by jeopardizing the timely completion of scheduled treatment sessions or by forcing reactive patients into unexpected changes in therapy. Rapid drug desensitization (RDD) enables these patients to receive their first-choice treatments safely. However, the possible effects of RDD on the efficacy of oxaliplatin have never been studied. Objective: The objective of this study was to evaluate the effect of RDD on survival rates in
more » ... val rates in oxaliplatin-hypersensitive patients. We performed a 7-year retrospective study to compare survival between oxaliplatin-hypersensitive cases (patients receiving oxaliplatin by RDD) and nonallergic controls (patients receiving standard oxaliplatin infusions). The primary endpoint of this study was overall survival (OS) in cases and controls (Kaplan-Meier method with log-rank test comparisons). OS was 23.7 months (95%CI, 15.3-30.9) for the 67 cases who underwent 337 RDDs, while for controls (n=143), OS was 34.5 months (95%CI, 21.7-55.5). There were no significant differences between the groups (HR, 1.42; 95%CI, 0.93-2.17; P =.104). Survival outcomes of oxaliplatin-hypersensitive patients who received oxaliplatin via RDD did not differ significantly from those of control patients who received oxaliplatin via standard administration. Receiving oxaliplatin by means of RDD might be an effective therapeutic alternative for oxaliplatin-hypersensitive patients.
doi:10.18176/jiaci.0425 pmid:31188129 fatcat:eypmtqtz7ffgjizsjrw7a4lwlu